Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277095 | 0.87 | PPARD (0.56) | PPARDL3MBTL1MAPTNPSR1TBXAS1 | |
| SCHEMBL10537253 | 0.86 | PPARD (0.61) | PPARDL3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL18301818 | 0.85 | L3MBTL1 (0.55) | L3MBTL1MAPTNPSR1KDM4ETDP1 | |
| SCHEMBL30591428 | 0.85 | L3MBTL1 (0.49) | L3MBTL1MAPTNPSR1KDM4EBRD4 | |
| SCHEMBL18066342 | 0.85 | L3MBTL1 (0.47) | PPARDL3MBTL1MAPTKDM4ETDP1 | |
| SCHEMBL6697391 | 0.84 | PPARD (0.50) | PPARDL3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL30104114 | 0.83 | TSHR (0.58) | PPARDL3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL7847681 | 0.83 | TSHR (0.58) | PPARDL3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL11732623 | 0.83 | PPARG (0.56) | PPARDMAPTNPSR1 | |
| SCHEMBL9798378 | 0.83 | PPARD (0.59) | PPARDL3MBTL1MAPTKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220267337-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | PDK1, PDK2, PDK3 | PPARD 290/4885L3MBTL1 1283/4885MAPT 3441/4885 |
| US-20220267337-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | PPARD 244/4885L3MBTL1 1751/4885MAPT 3365/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | PPARD 244/4885L3MBTL1 1751/4885MAPT 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.